AbCellera Biologics Inc. Files 8-K on Security Holder Vote Matters
Ticker: ABCL · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1703057
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
AbCellera is calling a shareholder vote, details to follow.
AI Summary
AbCellera Biologics Inc. filed an 8-K on June 13, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain specific details about the matters to be voted on or any associated financial implications.
Why It Matters
This filing indicates that AbCellera Biologics Inc. is convening a meeting or taking action that requires the approval of its shareholders, which could impact corporate governance or strategic decisions.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any new financial risks or material adverse events.
Key Players & Entities
- AbCellera Biologics Inc. (company) — Registrant
- June 13, 2024 (date) — Date of Report
FAQ
What specific matters will be submitted for a vote by AbCellera Biologics Inc. security holders?
The filing states that matters are being submitted to a vote of security holders, but does not specify what those matters are.
When is the earliest event reported in this 8-K filing?
The earliest event reported is June 13, 2024.
What is the principal executive office address for AbCellera Biologics Inc.?
The principal executive office is located at 2215 Yukon Street, Vancouver, BC V5Y 0A1.
What is the telephone number for AbCellera Biologics Inc.?
The telephone number is (604) 559-9005.
Under which section of the Securities Exchange Act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 683 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2024-06-13 16:53:28
Filing Documents
- abcl-20240613.htm (8-K) — 31KB
- 0001628280-24-028097.txt ( ) — 147KB
- abcl-20240613.xsd (EX-101.SCH) — 2KB
- abcl-20240613_lab.xml (EX-101.LAB) — 20KB
- abcl-20240613_pre.xml (EX-101.PRE) — 12KB
- abcl-20240613_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. AbCellera Biologics Inc. (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting") on June 13, 2024. As of April 15, 2024, the record date for the Annual Meeting, there were 293,921,356 common shares of the Company outstanding and entitled to vote at the Annual Meeting. The Company's shareholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2024: (i) to elect Vronique Lecault, Ph.D. and Andrew Lo, Ph.D. as Class I directors of the Company to serve for a three-year term expiring at the Company's annual meeting of shareholders in 2027 and until his or her successor has been elected and qualified ("Proposal 1"), (ii) to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 ("Proposal 2"), and (iii) to approve on a non-binding advisory basis, the compensation of the Company's named executive offices, or Say-on-Pay ("Proposal 3"). Proposal 1 The Company's shareholders approved the election of Vronique Lecault, Ph.D. and Andrew Lo, Ph.D. as Class I directors recommended for election in Proposal 1 at the Annual Meeting. The Company's shareholders voted for the Class I directors as follows: Nominee For Against Abstain Vronique Lecault, Ph.D. 167,328,506 6,868,582 15,059,808 Andrew Lo, Ph.D. 152,914,311 6,017,047 30,325,538 The broker non-votes for this Proposal 1 totaled 23,405,619 common shares. Proposal 2 The Company's shareholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain 211,978,251 306,801 377,463 Proposal 3 The Company's shareholders approved` Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain 176,566,724 7,454,852 5,235,320 The broker non-votes for this Prop
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 13, 2024 ABCELLERA BIOLOGICS INC. By: /s/ Carl L. G. Hansen Carl L. G. Hansen, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)